Acquired von Willebrand Syndrome: A Comprehensive Review and a Nordic Perspective
Seminars in Thrombosis and Hemostasis · 01.09.2026 · 52 (06) · 628-644
DOI: 10.1055/a-2765-9556 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Thrombosis and Hemostasis, erschienen am 01.09.2026. Verfasst von Eva Zetterberg und 9 weiteren Autor:innen. Beteiligte Einrichtung: Coagulation Unit, Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden. Hauptthemen laut MEDLINE: von Willebrand Diseases. Die Arbeit nennt 134 Literaturangaben.
Abstract (Originalsprache)
Acquired von Willebrand syndrome (AVWS) is a rare condition characterized by an acquired functional and/or absolute deficiency of the von Willebrand factor (VWF) protein. The absence of widely accepted diagnostic criteria has hampered accurate estimates of incidence and prevalence, which are largely currently unknown. As bleeding symptoms are not included in the most widely used definitions, AVWS should be managed as a risk factor for bleeding, rather than a specific disease entity. The diagnostic workup is cumbersome, involving measurement of both VWF antigen, VWF glycoprotein Ib binding activity, VWF collagen binding activity, and, preferentially, also VWF multimer analyses. Moreover, since the presence of bleeding symptoms is not required for diagnosis, the condition is probably underdiagnosed. In contrast to acquired hemophilia, AVWS is seldom caused by the presence of specific antibodies, but rather secondary to another disorder, most commonly lymphoproliferative, myeloproliferative, cardiovascular, and autoimmune disorders. Pathogenesis of AVWS varies according to the underlying disorder and includes nonspecific adsorption of VWF to antibodies, adsorption onto surfaces of neoplastic cells, mechanical injury, or VWF proteolysis. Treatment includes treating the underlying cause as well as stopping acute bleeds. Here, we present a comprehensive review of what is currently known regarding demographics, diagnostics, and clinical presentation of the syndrome. Since no prospective treatment studies have been performed, treatment choices must be based on data from registries and case reports that are also summarized. Moreover, we present treatment experiences of previously unpublished Nordic cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Coagulation Unit, Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden.
- Division of Laboratory Medicine, Coagulation Laboratory, Department of Clinical Chemistry and Pharmacology, University and Regional Laboratories Region Skåne, Malmö, Sweden.
- Department of Translational Medicine, Lund University, Lund, Sweden.
- Department of Translational Medicine, Lund University, Malmö, Sweden.
- Coagulation Disorders Unit, Department of Haematology, Helsinki University Hospital Comprehensive Cancer Centre and Helsinki University, Helsinki, Finland.
- Department of Haematology, Copenhagen University Hospital, Copenhagen, Denmark.
ORCID-Profile: Anne Louise Töllböll Sörensen
Zitieren
APA
Zetterberg, E., Strandberg, K., Hillarp, A., Nummi, V., Szanto, T., Lehtinen, A. E., Töllböll Sörensen, A. L., Olsson, A., Vaide, I., & Funding, E. (2026). Acquired von Willebrand Syndrome: A Comprehensive Review and a Nordic Perspective. Seminars in Thrombosis and Hemostasis, 52(06), 628-644. https://doi.org/10.1055/a-2765-9556
Vancouver
Zetterberg E, Strandberg K, Hillarp A, Nummi V, Szanto T, Lehtinen AE, et al. Acquired von Willebrand Syndrome: A Comprehensive Review and a Nordic Perspective. Seminars in Thrombosis and Hemostasis. 2026;52(06):628-644. doi:10.1055/a-2765-9556
BibTeX
@article{Zetterberg2026,
author = {Zetterberg, Eva and Strandberg, Karin and Hillarp, Andreas and Nummi, Vuokko and Szanto, Timea and Lehtinen, Anna-Elina and Töllböll Sörensen, Anne Louise and Olsson, Anna and Vaide, Ines and Funding, Eva},
title = {Acquired von Willebrand Syndrome: A Comprehensive Review and a Nordic Perspective},
journal = {Seminars in Thrombosis and Hemostasis},
year = {2026},
volume = {52},
number = {06},
pages = {628--644},
doi = {10.1055/a-2765-9556}
}
EUVIMED